Preprint
Article

This version is not peer-reviewed.

AI Decision Support for Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs

Submitted:

09 August 2026

Posted:

12 August 2026

You are already at the latest version

Abstract
Overview of Long COVID Long COVID, also known as Post-COVID Conditions (PCC), Post Acute Squeal of COVID PASC, or Chronic COVID, is the lingering consequence of a SARS-CoV-2 infection. While many infections like Influenza, Ebola, Malaria and Lyme Disease also carry severe post-infection risks, Long COVID emerged as a uniquely modern challenge because of the number of people who have it. The science and treatments of the condition are rapidly evolving; nonetheless, the condition remains ill-defined, and a definitive diagnostic test does not yet exist. The Global Scale While its 7% prevalence rate may seem modest, the sheer scale of the pandemic made this a global crisis. Assuming 75% of the world's population has been infected, an estimated 420 million people suffer from Long COVID. To put that in perspective, this is roughly five times the total number of people killed or injured in all 20th- and 21st-century wars combined. Risk Factors and Prevention Research suggests that inflammation, persistent viral infection, and mitochondrial dysfunction are the primary drivers of the condition. While risk fluctuates based on demographics and health, several factors reduce the likelihood of developing Long COVID: Demographics: Being younger, male, and maintaining high physical fitness. COVID Status: Recent viral variants, early use of antivirals, and-most importantly vaccination. The protective impact of vaccines is a subject of intense study. While the average reported reduction in Long COVID risk from vaccination is 50%, individual studies show a wide range of efficacy, from 10% to 100%. Data about the impact on individuals with comorbidities is similarly varied. Treatment: Seeking "Bronze BBs" There is no single curative therapy for Long COVID. “Bronze BBs” describes interventions that some studies report as providing incremental, organ-specific symptomatic relief for some patients. Reported effect sizes are heterogeneous, and many findings have not been replicated.
Keywords: 
;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2026 MDPI (Basel, Switzerland) unless otherwise stated

Accessibility

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings